Do Allergy Shots Make Allergies Worse? What the Published Data Shows

The published data shows allergy shots improve rather than worsen allergies at the population level. A Cochrane systematic review by Calderon et al. (2007) covering 51 randomized trials found a pooled standardized mean difference of -0.73 for symptom scores — a clinically meaningful improvement over placebo. Sixty to ninety percent of patients in systematic reviews achieve significant symptom and medication score reductions after 3–5 years of treatment. Some patients do experience temporary worsening during build-up — this is real, documented, and immunologically expected, but is transient rather than permanent in most cases who continue treatment.

Precise prevalence data for temporary allergy symptom worsening during SCIT build-up is not well-established in published literature because it was not a primary outcome measure in most trials — trials focused on long-term symptom improvement. Clinical observations document that a meaningful minority of patients experience worsening during build-up, but 'worsening' was not systematically tracked with validated instruments across large populations. What IS well-documented is the 10–30% premature discontinuation rate in immunotherapy adherence studies, with temporary worsening and side effects cited as key drivers. Persistent worsening that does not resolve by 12 months at maintenance dose is more concerning and has a documented prevalence of treatment failure around 10–25%.

Treatment failure in allergy immunotherapy means that a patient completes adequate build-up, reaches maintenance dose, and receives at least 12 months of maintenance treatment without achieving meaningful symptom improvement. This occurs in approximately 10–25% of patients across studies. Causes include: incorrect allergen selection (sensitizations not identified in testing were not included in extract), inadequate maintenance dosing, development of new sensitizations not covered in the original extract formulation, concurrent non-allergic disease (non-allergic rhinitis, chronic sinusitis with polyps) contributing to symptoms, or patient factors that reduce immunological response. Treatment failure warrants re-evaluation: repeat allergy testing, extract review, and consideration of alternative strategies — not simply continued treatment at the same protocol.

Paradoxical build-up worsening is a recognized clinical phenomenon, though its precise prevalence varies across patient populations and is not quantified with high precision in the literature. The mechanism is well-established: during build-up, escalating allergen doses stimulate the Th2 immune pathway before regulatory T cells and IgG4 blocking antibodies establish tolerance — patients may perceive this as symptom amplification (Akdis & Akdis, JACI, 2015). Clinical experience suggests it is more common in patients with severe baseline allergic disease, polysensitization, or peak-season starts. Most patients who push through this phase experience improvement as maintenance is reached. The 10–30% premature discontinuation rate suggests temporary worsening is a clinically significant barrier to treatment completion.

Tracking allergy symptoms during SCIT with a validated instrument provides the objective data needed to distinguish expected build-up worsening from treatment failure. The Total Nasal Symptom Score (TNSS) is the most widely used tool, rating four symptoms (runny nose, congestion, sneezing, nasal itching) on 0–3 scales for a total of 0–12. A reliable tracking protocol: measure TNSS before starting SCIT (baseline), monthly during build-up, and at 6, 12, 18, and 24 months of maintenance. Expected trajectory in a successful responder: stable or mild increase during build-up (weeks 4–16), beginning to improve by months 3–6, meaningful reduction by months 12–18. If TNSS at 12 months of maintenance shows no change from pre-treatment baseline, this signals treatment failure requiring re-evaluation. Bring tracked scores to every allergist follow-up appointment.

The evidence-based recommendation is to continue SCIT through build-up and at least 12 months of maintenance before concluding that treatment is not working. This means giving treatment a minimum of 18–24 months from initiation before considering discontinuation due to lack of efficacy. Many patients who notice no improvement at 6 months see meaningful improvement by 12–18 months — the immune tolerance build-up continues throughout the first years of treatment. Legitimate reasons to consider discontinuation earlier: severe systemic reactions at each injection visit despite dose adjustment, anaphylaxis episodes, unmanageable side effects despite optimization, or clearly worsening symptoms at maintenance dose that persist beyond 6 months (suggesting treatment failure rather than build-up phase worsening). Temporary build-up worsening alone, especially in the first 3–6 months, is generally not sufficient reason to abandon treatment that may provide long-term disease modification.

One of the strongest arguments for completing SCIT is the persistence of benefit after treatment ends. Durham et al.'s landmark New England Journal of Medicine study (1999) demonstrated sustained grass pollen allergy symptom reduction for at least 3 years after completing immunotherapy — with no comparable benefit in placebo-treated patients. Long-term follow-up data suggests benefits persist for 7–12 years after completing 3–5 years of treatment, though this varies by allergen type, treatment completion, and individual response. By contrast, antihistamines and nasal corticosteroids provide no sustained benefit after stopping — symptoms return immediately. This disease-modification advantage is the primary argument for completing SCIT despite temporary build-up challenges.